Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Longjiang She"'
Autor:
Siqi Tang, Zhenyu Wu, Lusi Chen, Longjiang She, Weihan Zuo, Weijun Luo, Yang Zhang, Shaoqiang Liang, Guichao Liu, Biyi He, Jinfeng He, Ning Zhang
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundNasopharyngeal carcinoma (NPC) is prevalent in Southern China. The expression profile and functions of kinesin family member 18B (KIF18B) remain unclear in NPC.MethodsBulk and single-cell transcriptome data for NPC were downloaded. KIF18B e
Externí odkaz:
https://doaj.org/article/abad0182abc2401a8b0a14b1110e5d09
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
BackgroundAdding metronomic capecitabine to concurrent chemoradiotherapy (CCRT) brings failure-free survival (FFS) benefits to patients with locoregionally advanced nasopharyngeal carcinoma (NPC). This study assesses the cost-effectiveness of metrono
Externí odkaz:
https://doaj.org/article/930dee17328f4e3a815ecad9de4b4859
Autor:
Huabin Hu, Longjiang She, Mengting Liao, Yin Shi, Linli Yao, Dong Ding, Youwen Zhu, Shan Zeng, David P. Carbone, Jin Huang
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Background: The CheckMate 227 trial has indicated that nivolumab plus ipilimumab compared with chemotherapy significantly increases long-term survival in the first-line setting of advanced non-small-cell lung cancer (NSCLC).Methods: A Markov model wa
Externí odkaz:
https://doaj.org/article/45321d69ce954fd8b668e7329a51f6b6
Autor:
Jiaqi Han MD, Desheng Xiao PhD, Chongqing Tan PhD, Xiaohui Zeng MD, Huabin Hu MD, Shan Zeng PhD, MD, Qin Jiang MD, Longjiang She MD, Linli Yao MD, Li Li MD, Lanhua Tang PhD, Jian Ma PhD, MD, Jin Huang PhD, MD, Liangfang Shen PhD, MD
Publikováno v:
Cancer Control, Vol 27 (2020)
Background: The FIRE-3 phase III clinical trial demonstrated the marked advantage of prolonging the median overall survival of patients with final RAS wild-type (WT) left-sided metastatic colorectal cancer (mCRC) by 38.3 months after treatment with i
Externí odkaz:
https://doaj.org/article/86f087976bbc451ea2f0a58444abe768
Autor:
Longjiang Shen, Shizhong He
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract A wealth of practical cases indicates that the fatigue failure of subway bogies primarily stems from the modal resonance of the structure. If the modal characteristics of the entire vehicle, including equipment and bogies, are mismatched, ra
Externí odkaz:
https://doaj.org/article/293fdffba99f4001a85e4caf48928101
Publikováno v:
Oral oncology. 129
Recently, updated data from KEYNOTE-048 revealed that pembrolizumab with or without chemotherapy could improve progression-free survival (PFS)2 compared with cetuximab plus chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72ca779f5cc52cb80821a952fa17dcbc
https://pubmed.ncbi.nlm.nih.gov/35483156
https://pubmed.ncbi.nlm.nih.gov/35483156
Publikováno v:
Advances in Mechanical Engineering, Vol 16 (2024)
Rack rail vehicles show strong capability of mountain climbing and have become a popular transportation mode for mountain areas in recent years. Therefore, this paper investigated on the dynamic performance of rack rail vehicle through simulation of
Externí odkaz:
https://doaj.org/article/7d54eebe46d046adbcb2a102932233f7
Publikováno v:
Journal of Low Frequency Noise, Vibration and Active Control, Vol 43 (2024)
In order to compare the differences in vibration before and after wheel re-profiling and assess the vibration impact of train under full-load and empty-load condition, the field vibration measurement was conducted on an underground metro track compon
Externí odkaz:
https://doaj.org/article/951be84bc38b4921a18285bab0b7f372
Autor:
Yin Shi, Linli Yao, Dong Ding, Jin Huang, Shan Zeng, Liangfang Shen, Longjiang She, Huabin Hu, Youwen Zhu
Publikováno v:
Oncologist
Background The data from the phase III clinical trial KEYNOTE-426 indicated that pembrolizumab plus axitinib compared with sunitinib could generate clinical benefits in patients with previously untreated advanced renal cell carcinoma (RCC). Given the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4271ea2f9f3f5816a6162001e5e57505
https://europepmc.org/articles/PMC7873332/
https://europepmc.org/articles/PMC7873332/
Autor:
Yin Shi, Huabin Hu, Youwen Zhu, Dong Ding, Mengting Liao, Jin Huang, Linli Yao, Longjiang She, Shan Zeng
Publikováno v:
Advances in therapy. 37(5)
The purpose of this study was to estimate the cost-effectiveness of atezolizumab plus chemotherapy in patients with metastatic non-squamous non-small cell lung cancer (NSCLC) from the United States (US) payers’ perspective in the first-line treatme
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e690fcbf15e2c4e075850c1e8846344
https://pubmed.ncbi.nlm.nih.gov/32193809
https://pubmed.ncbi.nlm.nih.gov/32193809